News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
pSivida Corp Reports Second Quarter Fiscal Year 2013 Results
February 7, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its second quarter ended December 31, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Mergers & acquisitions
Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together
October 2, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
GSK Cuts 8 Employees in San Francisco
October 2, 2025
·
211 min read
·
BioSpace Editorial Staff
Cell therapy
Takeda Exits Cell Therapy Amid Strategic Pivot, Dealing Blow to Once Promising Modality
October 2, 2025
·
2 min read
·
Tristan Manalac
Cancer
AnaptysBio Plans Business Split To Sharpen Focus on Asset Value
October 1, 2025
·
2 min read
·
Tristan Manalac
